Automated Author ProfileKoulogiannis, Konstantinos
Koulogiannis, Konstantinos
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 0.6 (sum of 2 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
As transcatheter therapies for mitral valve repair and replacement have increased, there exists a lack of clarity as to which patient and anatomic factors should determine patient selection for transcatheter repair versus replacement. At the request of the US Food & Drug Administration and under the auspices of the Heart Valve Collaboratory, a multi-disciplinary group convened to create this expert opinion document to identify patient and valvular factors that define non-suitability for transcatheter edge to edge repair, including 1) anatomic issues leading to the development of mitral stenosis, 2) anatomic factors associated with inadequate reduction in mitral regurgitation, 3) patient factors associated with inability to perform the TEER, and 4) clinical factors associated with futility in performing TEER. In such patients, barring futility, transcatheter mitral replacement could be considered.
Authors
- D. Scott Lim ;
- Herrmann, Howard C. ;
- Grayburn, Paul ;
- Koulogiannis, Konstantinos ;
- Gorav Ailawadi ;
- Williams, Mathew ;
- Ng, Vivian G. ;
- Chau, Katherine H. ;
- Sorajja, Paul ;
- Robert L. Smith 2nd ;
- Guerrero, Mayra ;
- Daniels, David ;
- Granada, Juan F. ;
- Mack, Michael J. ;
- Leon, Martin B. ;
- McCarthy, Patrick
As transcatheter therapies for mitral valve repair and replacement have increased, there exists a lack of clarity as to which patient and anatomic factors should determine patient selection for transcatheter repair versus replacement. At the request of the US Food & Drug Administration and under the auspices of the Heart Valve Collaboratory, a multi-disciplinary group convened to create this expert opinion document to identify patient and valvular factors that define non-suitability for transcatheter edge to edge repair, including 1) anatomic issues leading to the development of mitral stenosis, 2) anatomic factors associated with inadequate reduction in mitral regurgitation, 3) patient factors associated with inability to perform the TEER, and 4) clinical factors associated with futility in performing TEER. In such patients, barring futility, transcatheter mitral replacement could be considered.
Authors
- D. Scott Lim ;
- Herrmann, Howard C. ;
- Grayburn, Paul ;
- Koulogiannis, Konstantinos ;
- Gorav Ailawadi ;
- Williams, Mathew ;
- Ng, Vivian G. ;
- Chau, Katherine H. ;
- Sorajja, Paul ;
- Robert L. Smith 2nd ;
- Guerrero, Mayra ;
- Daniels, David ;
- Granada, Juan F. ;
- Mack, Michael J. ;
- Leon, Martin B. ;
- McCarthy, Patrick